Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures

To determine risk of osteoporosis and fractures associated with chemotherapy among elderly non-Hodgkin's lymphoma (NHL) patients, a cohort of 13 570 patients aged >= 65 years with incident NHL was identified from SEER-Medicare data with up to 11 years of follow-up. One year prior to the diagnosis, significantly fewer patients had fracture and osteoporosis claims in the chemotherapy group versus no chemotherapy group. However, after NHL diagnosis, patients who received chemotherapy had significantly higher rates of fracture (31% versus 19%, P < 50.001) and osteoporosis (10% versus 8%, P < 0.001), compared with those who did not. The risk of having fracture ( odds ratio 2.24, 95% Cl 2.04 - 2.45) and osteoporosis (odds ratio 1.27, 95% Cl = 1.12 - 1.45) was significantly higher in patients receiving chemotherapy compared with those who did not, after controlling for demographic and tumor factors. In conclusion, use of chemotherapy was significantly associated with increased risk of fracture and osteoporosis in elderly patients with NHL.